European Committee for Sports History

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

Retrieved on: 
Wednesday, September 29, 2021

NEW YORK, Sept. 29, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held virtually October 13 – 15, 2021. Regular abstracts are now available through the ECTRIMS platform and late-breaking abstracts will be accessible on October 13, 2021. Additional presentation details, including a direct link to the currently available abstract is included below.

Key Points: 
  • Regular abstracts are now available through the ECTRIMS platform and late-breaking abstracts will be accessible on October 13, 2021.
  • To attend the live event, please visit the Events page, located within the Investors & Media section, of the Company's website at http://ir.tgtherapeutics.com/events .
  • Following the live event, an archive file will be available for replay, for a period of 30 days after the call.
  • The ULTIMATE I & II trials enrolled a total of 1,094 patients with RMS across 10 countries.

ORYZON to Present New Clinical Data and Corporate Updates at International Conferences in September and October

Retrieved on: 
Wednesday, September 22, 2021

Oryzon will present preliminary data from the ongoing collaboration with INGEMM in Phelan McDermid Syndrome (PMS) at the International Conference on Autism, ICA-2021, which will be held on September 23-24.

Key Points: 
  • Oryzon will present preliminary data from the ongoing collaboration with INGEMM in Phelan McDermid Syndrome (PMS) at the International Conference on Autism, ICA-2021, which will be held on September 23-24.
  • The communication entitled "Phenotype and Psychometric Characterization of Phelan McDermid Syndrome Patients" will be presented by Dr. Carlos Buesa, Oryzons CEO.
  • Executive directors of the company will attend the BIO Spain 2021 event, which will take place September 27-October 1.
  • The company will moderate a KOL panel discussion on precision medicine therapeutic approaches for CNS disorders and the potential of LSD1 inhibitors like vafidemstat.